

August 11, 2023

**To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001**

**To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sirs,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you on the recommendation of Nomination & Remuneration Committee (NRC), the Board has approved promotion of senior managerial person (SMP), the details of the aforesaid change as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, as Annexure A.

You are requested to take the same on record.

Thanking You.  
Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber  
Company Secretary & Compliance Officer**

Encl: As above

Tel: 4018 9999 / 4018 9879  
Fax: 4018 9986 (Legal & Secretarial Dept.)

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

**Annexure I**

**Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Name & Designation of Director	Mr. Alok Malik President & Business Head - India Formulations
2.	Reason for change	Promoted from Executive Vice President to President & Business Head - India Formulations
3.	Date of appointment & term of appointment	Effective date – 11th August, 2023  Term – Not Applicable
4.	Brief Profile	Mr. Alok Malik currently manages portfolio of Dermatology, Respiratory, Oncology – Critical Care and OTC as major therapy areas. He is an accomplished marketing professional, with proven track record in sales & marketing and overall operation of large size business. He has managed life cycle of mature brands including launching over 100 brands in all the major therapy areas of IPM.  Alok is a science graduate and has done MBA from Indore University in 1989.
5.	Disclosure of relationships between directors (in case of appointment of a director)	None

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)